| non-alcoholic fatty liver disease | NAFLD |
| non-alcoholic fatty liver | NAFL |
| non-alcoholic steatohepatitis | NASH |
| metabolic-associated fatty liver disease | MAFLD |
| hepatic fibrosis | HF |
| palmitate | PA |
| methionine-choline deficient | MCD |
| low-density lipoprotein receptor knockout | LDLr−/− |
| lipopolysaccharide | LPSO |
| non-esterified fatty acid | NEFA |
| Yin Yang 1 | YY1 |
| fatty acid synthase | FAS |
| endoplasmic reticulum | ER |
| free fatty acids | FFA |
| carbon tetrachloride | CCl4 |
| thioacetamide | TAA |
| high-fat + high-carbohydrate diet | HFHCD |
| uncoupling protein-2 | UCP2 |
| liver X receptors | LXRs |
| anti-oxidant redux elements | ARE |
| over the counter | OTC |
| Food and Drug Administration | FDA |
| high-refined carbohydrate diet | HRCD |
| double knockout | DKO |
| wild-type | WT |
| β-carotene oxygenase 1 | BCO1 |
| β-carotene oxygenase 2 | BCO2 |
| sirtuin 1 | SIRT 1 |
| farnesoid X receptor | FXR |
| liver X receptor | LXR |
| sterol regulatory element binding proteins-1c | SREBP-1c |
| steroyl-coA desaturase-1 | SCD-1 |